Skip to main content
Premium Trial:

Request an Annual Quote

Lucier to Lead New ABI, DiVincenzo Takes Over at Millipore's Bioscience Division, Hood Joins Geospiza Board, and More

NEW YORK (GenomeWeb News) – Greg Lucier, chairman and CEO of Invitrogen, will assume that some role following consummation of the firm’s merger with Applied Biosystems. Mark Stevenson, currently president and COO of ABI, will retain that role in the merged company, which will keep the ABI name. Tony White, chairman, president, and CEO of ABI parent Applera, will serve as a consultant to ABI following the deal.

Millipore has appointed Jon DiVincenzo to be president of the company’s Bioscience Division, replacing Dominique Baly, who will leave at the end of 2008 after 36 years with the company.
DiVencenzo, who began at Millipore in 1994 and is currently VP of Global Sales and Service in the Bioscience Division, will begin in the new position at the beginning of 2009.

Genetic analysis software maker Geospiza said this week that Leroy Hood has joined the company’s board of directors. Hood is president and co-founder of the Institute for Systems Biology. He has been a researcher at Caltech, and he was founder of the University of Washington’s Department of Molecular Biotechnology. He also helped found biotech industry bellwethers Amgen and Applied Biosystems.

Oxford Nanopore Technologies has appointed John Milton to be director of nanopore chemistry and Clive Brown to be director of bioinformatics and IT, the molecular detection and analysis company said this week
Milton formerly was senior director of research at Solexa, where he worked on developing the company’s sequencing technology, and he also has worked at GlaxoWellcome and at Xenova. Brown was involved in developing informatics for next-generation sequencing technology at the Wellcome Trust Sanger Institute and he was director of computational biology and IT at Solexa.

Znomics has appointed Bruce Beutel to succeed Roger Cone as chief scientific officer. Cone has accepted the role of chairman of Vanderbilt University Medical Center’s Department of Molecular Physiology and Biophysics, a position he will begin in August. Cone will remain a member of the company’s board of directors.
Beutel formerly worked with Abbott Laboratories, where he was a senior project director in biology and metabolic disease research, and he also was a senior scientist at PharmaGenics.

GenVault said this week it has appointed Paul Mirabella to its board of directors. Mirabella is chairman and CEO of Naviscan PET Systems, and he formerly was president and CEO of Global Diagnostic Imaging and he was a senior leader at GE Healthcare.

Gene Express has appointed Michael Rowe to be senior VP of global marketing.
Rowe formerly was director of cardiovascular marketing at Women First Healthcare, senior marketing director at Pfizer, director of global outcomes research and strategic marketing at Allergan, and manager of international marketing and marketing research at Warner-Lambert Company.

Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in PEOPLE, a weekly roundup of industry comings and goings.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.